UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934 (Amendment No.)*

AQUAMED TECHNOLOGIES, INC.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

N/A

(CUSIP Number)

Rick A. Werner, Esq. Haynes and Boone, LLP 30 Rockefeller Plaza, 26th Floor New York, New York 10112 (212) 659-7300

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

September 10, 2019

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. N/A	
1. Names of Reporting	g Persons
Nachum Stein	
2. Check the Appropr (a) □ (b) ☑	iate Box if a Member of a Group (See Instructions)
3. SEC Use Only	
4. Source of Funds (S	ee Instructions)
PF	
5. Check if Disclosure	e of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6. Citizenship or Place	e of Organization
USA	
Number of Shares Beneficially Owned by	7. Sole Voting Power 1,634,750
Each Reporting Person With	8. Shared Voting Power 0
	9. Sole Dispositive Power
	1,634,750
	10. Shared Dispositive Power
	0
11. Aggregate Amour	t Beneficially Owned by Each Reporting Person
1,634,750	
12. Check if the Aggr	egate Amount in Row (11) Excludes Certain Shares (See Instructions)
13. Percent of Class R	Represented by Amount in Row (11)
19.8% (1)	
14. Type of Reporting	Person (See Instructions)
IN	

(1) Based upon 8,274,711 shares of common stock of the issuer, which consists of (i) 5,005,211 shares of common stock outstanding as of September 6, 2019, as disclosed in the issuer's Quarterly Report on Form 10-Q for the three months ended June 30, 2019, filed on September 9, 2019, by the issuer with the U.S. Securities and Exchange Commission and (ii) 3,269,500 shares of common stock issued pursuant to the Private Placement (as defined herein).

Item 1. Security and the Issuer

This Schedule 13D (this "Schedule 13D") relates to the common stock, par value \$0.001 per share (the 'Common Stock'), of AquaMed Technologies, Inc., a Delaware corporation (the 'Issuer'). The address of the principal executive offices of the Issuer is 2150 Cabot Blvd West, Suite B, Langhorne, PA 19047.

Item 2. Identity and Background

- (a) The name of the person filing this Schedule 13D is Nachum Stein (the '*Reporting Person*'').
- (b) The principal business address of the Reporting Person is 2150 Cabot Blvd West, Suite B, Langhorne, PA 19047.

(c) The Reporting Person is the record and direct beneficial owner of the Common Stock covered by this Schedule 13D. The principal occupation of the Reporting Person is serving as director of the Issuer.

(d) and (e) During the last five years, the Reporting Person has not been convicted in a criminal proceeding or been a party to a civil proceeding, in either case of the type specified in Items 2(d) or (e) of Schedule 13D.

(f) The Reporting Person is a citizen of USA.

Item 3. Source and Amount of Funds or other Consideration

On September 10, 2019, the Reporting Person entered a Securities Purchase Agreement (the "*Purchase Agreement*") with the Issuer and certain other accredited investors (together with the Reporting Person, the "*Investors*"). Pursuant to the Purchase Agreement, the Issuer agreed to sell to the Investors, and the Investors agreed to purchase, an aggregate of up to \$175,000 of shares of Common Stock on the initial closing date (the "*Initial Closing*"), and an aggregate of up to \$575,000 of shares of Common Stock on the initial closing date (the "*Initial Closing*"), and an aggregate of up to \$575,000 of shares of Common Stock on a subsequent closing date (the "*Purchase Price*") (the "*Purchase Price*") (the "*Private Placement*"). The Purchase Agreement provides that in the event that the Purchase Agreement is amended between Initial Closing and the Subsequent Closing to reduce the Per Share Purchase Price, then the Investors in the Initial Closing shall be entitled to receive from the Issuer additional shares of common stock purchase dpurchase Agreement (collectively the "*Shares*") then held, when divided by the total number of Shares acquired by such Investor at the Initial Closing plus such additional shares of Common Stock issued will equal the reduced Purchase Price.

The Purchase Agreement contains representations and warranties of the Investors and the Issuer that are typical for transactions of this type.

On September 10, 2019, the Initial Closing occurred, and the Reporting Person purchased 1,634,750 Shares at the Per Share Purchase Price.

The foregoing description of the Purchase Agreement is qualified in its entirety by reference to the Purchase Agreement, which is attached as Exhibit 99.1 hereto and incorporated by reference herein.

Item 4. Purpose of Transaction

The Reporting Persons acquired shares of Common Stock of the Issuer for investment purposes. Subject to applicable law and regulations, and depending upon certain factors, including without limitation, general market and investment conditions and the financial performance of the Issuer, the Reporting Person may have further discussions and other communications with other shareholders of the Issuer and may take actions that could result in, among other things: (a) the acquisition by the Reporting Person of additional Common Stock or other securities of the Issuer, or the disposition of Common Stock or other securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) changes in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the Board of Directors; (e) a material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's certificate of incorporation or bylaws or other actions which may impede the acquisition of control of the Issuer by any person; (h) causing any class of the Issuer's securities to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or (j) any action similar to those enumerated above.

The Reporting Person intends to review his investment in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the Issuer's financial position and strategic direction, the outcome of the discussions and actions referenced above, actions taken by the Board of Directors and management of the Issuer, changes to the composition of the Board of Directors, price levels of the shares of Common Stock, other investment opportunities available to the Reporting Person, conditions in the securities markets and general economic and industry conditions, the Reporting Person may in the future take such actions and/or pursue such options with respect to its investment in the Issuer as the Reporting Person deems appropriate under the circumstances.

Except to the extent that the foregoing may be deemed to be a plan or proposal, the Reporting Person currently does not have any plans or proposals that relate to or would result in any of the actions specified in clause (a) through (j) of Item 4 of Schedule 13D. Depending upon the foregoing factors and to the extent deemed advisable in light of the Reporting Person's general investment policies, or other factors, the Reporting Person may, at any time and from time to time, formulate other purposes, plans or proposals regarding the Issuer or the shares of Common Stock, or any other actions that could involve one or more of the types of transactions or have one or more of the results described in paragraphs (a) through (j) of Item 4 of Schedule 13D. The foregoing is subject to change at any time, and there can be no assurance that the Reporting Person will take any of the actions set forth above.

Item 5. Interest in Securities of the Issuer

(a) The aggregate number and percentage of the class of securities identified pursuant to Item 1 beneficially owned by the Reporting Person is stated in Items 11 and 13 on the cover page(s) hereto.

- (b) Number of shares as to which the Reporting Person has:
 - (i) sole power to vote or to direct the vote:

See Item 7 on the cover page(s) hereto.

(ii) shared power to vote or to direct the vote:

See Item 8 on the cover page(s) hereto.

(iii) sole power to dispose or to direct the disposition of:

See Item 9 on the cover page(s) hereto.

(iv) shared power to dispose or to direct the disposition of:

See Item 10 on the cover page(s) hereto.

(c) Other than the Reporting Person's purchase of 1,634,750 shares of Common Stock in the Private Placement, there were no transactions in the Common Stock that were effected during the past sixty days by the Reporting Person.

- (d) Not applicable.
- (e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

The information set forth in Item 3 of this Schedule 13D is hereby incorporated herein by reference.

Except as otherwise described herein, the Reporting Person does not have any legal or other contract, arrangement, understanding, or relationship with any other person with respect to the Common Stock or any other securities of the Issuer.

Item 7. Material to be Filed as Exhibits

The following exhibits are filed as exhibits hereto:

Exhibit	Description of Exhibit
<u>99.1</u>	Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Issuer filed on September 25, 2019 by the Issuer with the SEC).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 2, 2019

NACHUM STEIN

/s/ Nachum Stein